Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: A case series evaluating the impact of Hepatitis C eradication using direct acting antivirals on primary biliary cholangitis-associated autoimmunity

Fig. 2

a Titres of anti-mitochondrial antibody M2 (AMA-M2) and anti-3E-BPO during HCV therapy with ledipasvir (LDV) and sofosbuvir (SOF) X 12 weeks in Patient 1. LDV + SOF therapy was given between the dates of November 29, 2014 to February 20, 2015 (black box). Antibody titres were measured at three different time points as shown in the X-Axis. b Titres of anti-TRIM21/Ro52 and anti-3E-BPO during HCV therapy with ledipasvir (LDV) + sofosbuvir (SOF) X 24 weeks in Patient 2 LDV + SOF was given between the dates January 15, 2015 to July 2, 2015 (black box). Autoantibody titres were measured at various time points as shown in the X-Axis. c Titres of anti-mitochondrial antibody (AMA-M2) and anti-3E-BPO during HCV therapy with Sofosbuvir (SOF) and Ribavirin (RBV) X 24 weeks in Patient 3 SOF + RBV therapy was given between the dates of October 23, 2014 to April 8, 2015 (black box). Autoantibody titres were measured at various time points as shown in the X-Axis

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us